- Home
- BMA vs BPMC Comparison
BMA vs BPMC Comparison
Compare BMA & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- BPMC
- Stock Information
- Founded
- BMA 1966
- BPMC 2008
- Country
- BMA Argentina
- BPMC United States
- Employees
- BMA N/A
- BPMC N/A
- Industry
- BMA Commercial Banks
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- BPMC Health Care
- Exchange
- BMA Nasdaq
- BPMC Nasdaq
- Market Cap
- BMA 6.3B
- BPMC 5.8B
- IPO Year
- BMA 2006
- BPMC 2015
- Fundamental
- Price
- BMA $75.21
- BPMC $87.11
- Analyst Decision
- BMA Hold
- BPMC Buy
- Analyst Count
- BMA 3
- BPMC 22
- Target Price
- BMA $50.83
- BPMC $124.29
- AVG Volume (30 Days)
- BMA 265.2K
- BPMC 990.8K
- Earning Date
- BMA 05-21-2025
- BPMC 05-01-2025
- Dividend Yield
- BMA 7.12%
- BPMC N/A
- EPS Growth
- BMA N/A
- BPMC N/A
- EPS
- BMA 0.49
- BPMC N/A
- Revenue
- BMA $4,443,772,797.00
- BPMC $508,824,000.00
- Revenue This Year
- BMA N/A
- BPMC $45.57
- Revenue Next Year
- BMA $5.76
- BPMC $32.14
- P/E Ratio
- BMA $19.08
- BPMC N/A
- Revenue Growth
- BMA N/A
- BPMC 104.04
- 52 Week Low
- BMA $42.23
- BPMC $80.68
- 52 Week High
- BMA $118.42
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- BMA 38.76
- BPMC 42.87
- Support Level
- BMA $73.05
- BPMC $84.55
- Resistance Level
- BMA $77.89
- BPMC $90.39
- Average True Range (ATR)
- BMA 3.91
- BPMC 3.56
- MACD
- BMA -0.23
- BPMC 0.08
- Stochastic Oscillator
- BMA 17.93
- BPMC 22.32
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.